2024 г
Safety and specific activity of the recombinant SARS-CoV-2 allergen (“CoronaDerm-PS”) based on phase I–II clinical trial results
Russian Journal of Infection and Immunity. – 2024. – Т. 14. – №. 5. – С. 900-916
Savin T.V., Milichkina A.M., Krasnov A.A., Kuznetsova R.N., Shchederkina E.E., Svarval A.V., Sharova A.А., Reingardt D.E., Ostankova Y.V., Gubanova A.V., Petrova O.A., Zhimbaeva O.B., Razumovskaya A.P., Drozd I.V., Rubinstein A.А., Trulev A.S., Kudryavtsev I.V., Riabchenkova A.A., Chirak E.L., Chirak E.R., Saenko A.I., Kopat V.V., Dukhovlinov I.V., Simbirtsev A.S., Totolian A.A.